Panacea Life Sciences Holdings, Inc. (PLSH) stock
Close on Oct 19, 2026Market cap $1.15MP/E –Yield –
Panacea Life Sciences Holdings, Inc. grew revenue 50.4% to $2.76M over the twelve months to Mar 31, 2024. Free cash flow was -$1.59M. At the latest close the market valued the company at $1.15M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Mar 31, 2024
Valuation
- Market cap
- $1.15M
- P/E ratio
- –
- Price to sales
- 0.42
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -138.50%
Fundamentals
- Revenue
- $2.76M
- Net income
- -$7.67M
- EPS, diluted
- -$0.46
- Free cash flow
- -$1.59M
- Book value per share
- -$0.58
- Diluted shares
- 16M
Trading
- Previous close
- $0.07
- Open
- $0.07
- Day's range
- $0.07 – $0.07
- Volume
- 2,000
- Average volume (20 days)
- 3,817
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | PLSH | S&P 500 | Difference | PLSH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -4.0% | +0.6% | −4.6 pts | ||
| 3 months | -7.2% | +3.4% | −10.6 pts | ||
| Year to date | +39.2% | +13.3% | +25.9 pts | ||
| 1 year | -0.6% | +16.6% | −17.2 pts | ||
| 3 years | -75.1% | +86.4% | −161.5 pts | -37.1% | +23.1% |
Eleven years at a glance
Fiscal years 2013 to 2023 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Panacea Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- News
- Update
- Update
- Update
About Panacea Life Sciences
Medicinal Chemicals & Botanical Products
Panacea Life Sciences Holdings, Inc. develops, manufactures, researches, and distributes plant-based health products, including nutraceuticals, cannabinoids, functional mushrooms, and kratom. The company operates through business segments that provide branded natural remedies under lines such as PANA Health, PANA Beauty, and PANA Sport, along with white-label licensing and contract manufacturing of softgels for external businesses. Additionally, it sells botanical beverages, teas, and alternative wellness items through corporate-owned retail locations and distribution operations. Its customer base includes individual consumers reached via e-commerce and retail storefronts, as well as healthcare providers, dispensaries, and business clients.
Company profile, executives and historyPanacea Life Sciences stock: common questions
What is Panacea Life Sciences's stock price?
PLSH closed at $0.07 on Oct 19, 2026, up 5.45% on the day.
What is Panacea Life Sciences's market cap?
Panacea Life Sciences was worth $1.15M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is PLSH's P/E ratio?
Panacea Life Sciences lost money over the twelve months to Mar 31, 2024 (diluted EPS -$0.46), so it has no meaningful P/E ratio.
How much revenue does Panacea Life Sciences make?
Panacea Life Sciences reported revenue of $2.76M for the twelve months to Mar 31, 2024, up 50.4% from a year earlier.
Does Panacea Life Sciences pay a dividend?
No. Panacea Life Sciences has not paid a cash dividend over the last twelve months.
How has PLSH stock performed over the past year?
Including dividends, PLSH returned -0.6% over the past year, against +16.6% for the S&P 500.
Who are Panacea Life Sciences's competitors?
Companies most similar to Panacea Life Sciences by business, industry and size include NTRR, CYAN, FTLF, HYEX, NAII.
See a number that looks wrong?